Human STAT1 gain of function with chronic mucocutaneous candidiasis: A comprehensive review for strengthening the connection between bedside observations and laboratory research

Abstract

SummaryGermline human heterozygous STAT1 gain‐of‐function (GOF) variants were first discovered a common cause of chronic mucocutaneous candidiasis (CMC) in 2011. Since then, numerous STAT1 GOF variants have been identified. A variety of clinical phenotypes, including fungal, viral, and bacterial infections, endocrine disorders, autoimmunity, malignancy, and aneurysms, have recently been revealed for STAT1 GOF variants, which has led to the expansion of the clinical spectrum associated with STAT1 GOF. Among this broad range of complications, it has been determined that invasive infections, aneurysms, and malignancies are poor prognostic factors for STAT1 GOF. The effectiveness of JAK inhibitors as a therapeutic option has been established, although further investigation of their long‐term utility and side effects is needed. In contrast to the advancements in treatment options, the precise molecular mechanism underlying STAT1 GOF remains undetermined. Two primary hypotheses for this mechanism involve impaired STAT1 dephosphorylation and increased STAT1 protein levels, both of which are still controversial. A precise understanding of the molecular mechanism is essential for not only advancing diagnostics but also developing therapeutic interventions. Here, we provide a comprehensive review of STAT1 GOF with the aim of establishing a stronger connection between bedside observations and laboratory research.

Chinese Chronic Mucocutaneous Candidiasis: A Case Report Series

“…We observed a gradual increase in cases favoring the functional acquisition of STAT1 due to gene mutations. 36 …”

“…We observed a gradual increase in cases favoring the functional acquisition of STAT1 due to gene mutations. 36 There are significant challenges in treating CMC due to its genetic predisposition and T-cell dysfunction, leading to limited effective therapeutic options. Currently, clinical treatments mainly include the use of antifungal drugs such as amphotericin B, fluconazole, itraconazole, voriconazole, and topical nystatin.…”